Veröffentlichungsdatum: 27 August 2014
Projektträger – zwischengeschaltetes Finanzinstitut
The project concerns the R&D programme of six highly strategic and amongst the company's most promising drug development projects. The compounds concerned are in different stages of development, and address unmet needs.
The project comprises a number of R&D sub-projects with different durations and objectives. By addressing the unmet medical needs and by offering new treatments with higher efficacy, tolerability and safety, the net economic returns to society should be very high. A project of this type should accelerate research and bring improved quality of life for patients currently suffering from the related illnesses.
- Gesundheit - Gesundheits- und Sozialwesen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 148 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 440 million
The R&D is conducted in state of the art buildings and the research and production facilities are subject to regular audits by competent authorities.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. Procurement procedures followed are in line with industry practice and satisfactory to the Bank.
Unterzeichnet - 16/06/2014
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).